EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Developing pioneering pharmacological strategies with CRISPR/Cas9 library screening to overcome cancer drug resistance

Yu He, Huan Li, Xueming Ju, Bo Gong

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024-11 · 1879 (6) · 189212

DOI: 10.1016/j.bbcan.2024.189212 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024-11. Verfasst von Yu He und 3 weiteren Autor:innen. Beteiligte Einrichtung: Human Disease Genes Key Laboratory of Sichuan Province and Institute of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Drug Resistance, Neoplasm, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 195 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer drug resistance is a major obstacle to the effectiveness of chemoradiotherapy, targeted therapy, and immunotherapy. CRISPR/Cas9 library screening has emerged as a powerful genetic screening tool with significant potential to address this challenge. This review provides an overview of the development, methodologies, and applications of CRISPR/Cas9 library screening in the study of cancer drug resistance. We explore its role in elucidating resistance mechanisms, identifying novel anticancer targets, and optimizing treatment strategies. The use of in vivo single-cell CRISPR screens is also highlighted for their capacity to reveal T-cell regulatory networks in cancer immunotherapy. Challenges in clinical translation are discussed, including off-target effects, complexities in data interpretation, and model selection. Despite these obstacles, continuous technological advancements indicate a promising future for CRISPR/Cas9 library screening in overcoming cancer drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsDrug Resistance, NeoplasmNeoplasmsAnimalsHumansAntineoplastic AgentsGene Library

Stichwörter der Autor:innen

CRISPR/Cas9 library screeningClinical translationGenetic screening toolIn vivo single-cell CRISPR screenscancer drug resistance

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Human Disease Genes Key Laboratory of Sichuan Province and Institute of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

He, Y., Li, H., Ju, X., & Gong, B. (2024). Developing pioneering pharmacological strategies with CRISPR/Cas9 library screening to overcome cancer drug resistance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1879(6), 189212. https://doi.org/10.1016/j.bbcan.2024.189212

Vancouver

He Y, Li H, Ju X, Gong B. Developing pioneering pharmacological strategies with CRISPR/Cas9 library screening to overcome cancer drug resistance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(6):189212. doi:10.1016/j.bbcan.2024.189212

BibTeX
@article{He2024,
  author = {He, Yu and Li, Huan and Ju, Xueming and Gong, Bo},
  title = {Developing pioneering pharmacological strategies with CRISPR/Cas9 library screening to overcome cancer drug resistance},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2024},
  volume = {1879},
  number = {6},
  pages = {189212},
  doi = {10.1016/j.bbcan.2024.189212}
}
Kostenlos starten →